Fovinaciclib versus placebo combined with fulvestrant for advanced breast cancer after endocrine therapy: A randomized, double-blind phase 3 trial.

作者
Xichun Hu,Yunjiang Liu,Biyun Wang,Zhongsheng Tong,Hongtao Li,Geng Zhang,Liuliu Zhang,Jingna Wu,Cailing Jin,Jianyun Nie,Sijuan Ding,Tienan Yi,Wei Li,Xujuan Wang,Xingli Wang,Yuhui Peng,Lize Li,Xiaoran Yang,FCN-437c-III202 Investigators
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 1101-1101
标识
DOI:10.1200/jco.2026.44.16_suppl.1101
摘要

1101 Background: Approximately 70% breast cancer (BC) patients have hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative disease. Fovinaciclib is a novel, potent, oral selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. A multicenter, randomized, double-blind, placebo-controlled phase 3 trial was conducted to compare fovinaciclib versus placebo plus fulvestrant in patients with advanced BC that relapsed or progressed on previous endocrine therapy. Methods: Eligible patients were randomly assigned (1:1) to receive 200 mg fovinaciclib (fovinaciclib arm) or placebo (placebo arm) orally once daily on days 1–21 in 28-day cycles. All patients also received intramuscular fulvestrant 500 mg (cycle 1: days 1 and 15; subsequent cycles: day 1). Premenopausal or perimenopausal patients also received subcutaneous goserelin 3.6 mg (day 1). The primary endpoint was blinded independent central review (BICR)-assessed progression-free survival (PFS). Secondary endpoints included other efficacy endpoints and safety. Exploratory endpoints included patient-reported outcomes. Results: A total of 319 patients were randomized to the fovinaciclib ( n = 160) or placebo arm ( n = 159). Baseline characteristics were balanced. Interim analysis at 9-month median follow-up (data cutoff date May 11, 2023) showed significant PFS benefit from adding fovinaciclib (p = 0.0001). Sustained PFS benefit of greater extent (median 14.0 months versus 5.6 months, hazard ratio 0.48, 95% confidence interval 0.36–0.65) was observed at updated analysis at 23-month follow-up (data cutoff date August 30, 2024). Trends of the PFS benefit were observed in all subgroups. Consistent improvements were observed in investigator-assessed PFS and objective response rate, disease control rate, clinical benefit rate, duration of response, and time to progression according to BICR or investigator's assessments. At updated analysis, all patients in the fovinaciclib arm and 148 (93.7%) in the placebo arm reported at least 1 treatment-emergent adverse event (TEAE). The most common TEAEs were hematological toxicities. TEAEs leading to study drug discontinuation were reported in 9 (5.6%) and 2 (1.3%) patients in the respective arms. No grade ≥3 venous thromboembolism or interstitial lung disease was reported. The two arms showed similar overall longitudinal profiles of global health status, function domains and symptom domains assessed with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire. Conclusions: Adding fovinaciclib to fulvestrant conferred statistically significant and clinically meaningful PFS benefit and consistent improvements in other survival outcomes, along with manageable safety. These findings support fovinaciclib as a later-line option. Clinical trial information: NCT05438810 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
Serendipity发布了新的文献求助10
3秒前
汤圆发布了新的文献求助10
4秒前
海鲸发布了新的文献求助20
4秒前
在望的应助被肖馨余采纳,获得10
4秒前
爱撒娇的朋友完成签到,获得积分10
5秒前
烟花的应助被flash采纳,获得10
6秒前
积极亦竹发布了新的文献求助10
6秒前
xiaxi完成签到,获得积分10
8秒前
ding的应助被xielaoban采纳,获得10
8秒前
9秒前
荼蘼发布了新的文献求助10
9秒前
10秒前
朴实颤完成签到,获得积分10
10秒前
11秒前
11秒前
chuqing发布了新的文献求助10
11秒前
momo完成签到,获得积分10
11秒前
无私的迎松完成签到,获得积分10
13秒前
YYJ完成签到,获得积分10
13秒前
酷波er的应助被积极亦竹采纳,获得10
14秒前
BAEKHYUNLUCKY发布了新的文献求助10
16秒前
16秒前
16秒前
16秒前
尘_发布了新的文献求助10
17秒前
BernardGo发布了新的文献求助10
20秒前
荼蘼发布了新的文献求助10
20秒前
慈祥的丹寒完成签到 ,获得积分10
24秒前
24秒前
冯老三完成签到 ,获得积分10
25秒前
Maestro_S的应助被chuqing采纳,获得10
25秒前
howeVer完成签到 ,获得积分10
25秒前
槟洛完成签到,获得积分10
25秒前
月亮代表我的心完成签到,获得积分10
26秒前
黄大树完成签到,获得积分10
26秒前
高挑的伊完成签到,获得积分10
27秒前
正直的又柔完成签到,获得积分10
28秒前
丘比特的应助被老年学术废物采纳,获得10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566955
关于积分的说明 21789278
捐赠科研通 7769593
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241